Skip to main navigation Skip to search Skip to main content

A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine-Adults & 12-36 mo.

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date01/28/20 → 01/27/23

Funding

  • ModernaTX: $48,168.50